Dr. Jotte on the IMpower131 Findings in Squamous NSCLC

Video

Robert M. Jotte, MD, PhD, medical director and co-chair, USON Thoracic Committee, Rocky Mountain Cancer Centers, discusses the phase III findings of the IMpower131 trial, which looked at the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) in patients with advanced squamous non

Robert M. Jotte, MD, PhD, medical director and co-chair, USON Thoracic Committee, Rocky Mountain Cancer Centers, discusses the phase III findings of the IMpower131 trial, which looked at the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) in patients with advanced squamous non-small cell lung cancer (NSCLC). Jotte discussed these findings in an interview with OncLive during the 2018 ASCO Annual Meeting.

IMpower131 was a 1000-patient study in treatment-naive patients with squamous NSCLC and, regardless of their level of PD-L1 expression, were randomized to receive carboplatin and paclitaxel plus atezolizumab (arm A), carboplatin and nab-paclitaxel plus atexolixumab (arm B) and carboplatin and paclitaxel (arm C), explains Jotte.

The primary endpoints of the study were investigator-assessed progression-free survival and overall survival. Data showed that arms B and C, which were able to analyzed at this time, demonstrated that a doubling in PFS from 12% in the control arm to 24.7% in the atezolizumab-containing arm, and the response rates increased in the PD-L1—high category from 33% to 60%, and the duration of response was also improved, concludes Jotte.

<<< 2018 ASCO Annual Meeting

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania